@article {Goswami2020.08.09.20170985, author = {Rudra Prosad Goswami and Uma Kumar and Maumita Kanjilal and Debaditya Ray and Pallavi Vij and Dheeraj K Mittal and Laxman Meena and Sandeep Nagar and Danveer Bhadu}, title = {COVID-19 in rheumatic diseases: A random cross-sectional telephonic survey}, elocation-id = {2020.08.09.20170985}, year = {2020}, doi = {10.1101/2020.08.09.20170985}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objective To describe the incidence, clinical course, and predictive factors of coronavirus 2019 (COVID-19) infection in a cohort of rheumatological patients residing in New Delhi (National Capital Region), India.Methods We performed a cross-sectional, random telephonic survey from 20th April to 20th July 2020 on patients with rheumatic diseases. Patients were interviewed with a predesigned questionnaire. The incidence of COVID-19 in the general population was obtained from open access government data repository. Report of reverse transcriptase polymerase chain reaction report was taken as confirmatory of COVID-19 infection.Results Among the 900 contacted patients 840 responded (713 with rheumatoid arthritis (RA), 100 with systemic lupus erythematosus (SLE), 20 with spondylarthritis (SpA) and 7 with others; mean age 45 {\textpm}13 years, mean duration 11.3 {\textpm} 6.3 years; 86\% female). Among them 29 reported flu-like symptoms and four RA patients had confirmed COVID-19 infection. All of them were hospitalized with uneventful recovery. Rheumatological drugs were discontinued during the infectious episode. Disease modifying agents and biologics were equally received by those with or without COVID-19. The incidence of COVID-19 was similar to general Delhi population (0.476\% vs 0.519\% respectively, p=0.86). Two patients had relapse of rheumatic disease after recovery. After recovery from COVID-19 or Flu-like illness, eight patients (27.6\%, 95\% confidence interval 14.7-45.7) reported disease flare.Conclusion Patients with rheumatic diseases in India have similar incidence of COVID-19 infection compared to the community. Relapse of underlying rheumatic disease after recovery is not uncommon and continuation of glucocorticoid through the infection should be considered.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by Institute Research Project, All India Institute of Medical Sciences, New Delhi, No.F.5-59/IRG/2010/RSAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the institutional review board of AIIMS, New Delhi (no. IEC-280/17.4.2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available with the corresponding author}, URL = {https://www.medrxiv.org/content/early/2020/08/13/2020.08.09.20170985}, eprint = {https://www.medrxiv.org/content/early/2020/08/13/2020.08.09.20170985.full.pdf}, journal = {medRxiv} }